Using hormone therapy with salvage radiotherapy according to presalvage PSA levels
- PMID: 32424273
- DOI: 10.1038/s41585-020-0333-9
Using hormone therapy with salvage radiotherapy according to presalvage PSA levels
Comment on
-
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.JAMA Oncol. 2020 May 1;6(5):735-743. doi: 10.1001/jamaoncol.2020.0109. JAMA Oncol. 2020. PMID: 32215583 Free PMC article. Clinical Trial.
References
-
- Locke, J. et al. Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nat. Rev. Urol. 12, 193–204 (2015). - DOI
-
- Shipley, W. U. et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N. Engl. J. Med. 376, 417–428 (2017). - DOI
-
- Carrie, C. et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 17, 747–756 (2016). - DOI
-
- Carrie, C. et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 20, 1740–1749 (2019). - DOI
-
- Valicenti, R. K. et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int. J. Radiat. Oncol. Biol. Phys. 86, 822–828 (2013). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
